Please wait while the formulary information is being retrieved.
TRANSDERM-SCOP (SCOPOLAMINE HYDROBROMIDE)
- Prevention of motion sickness
- Motion sickness
- Prevention of post-operative nausea and vomiting
- Transderm-scop Transdermal Patch, 3 Day
- Transderm-scop Transdermal Patch
- Transderm-scop Transdermal 72 Hour Patch
- Scopolamine Transdermal Patch, 3 Day
- By Indication
1.5 mg transdermal patch (1 mg over 3 days)
- Apply 1 patch by transdermal route to the hairless area behind 1 ear at least 4 hr before effect is required; reapply every 3 days as needed
1.5 mg transdermal patch (1 mg over 3 days)
- Apply 1 patch by transdermal route to the hairless area behind 1 ear at least 4 hr before effect is required; reapply every 3 days as needed
1.5 mg transdermal patch (1 mg over 3 days)
- Apply 1 patch by transdermal route to the hairless area behind 1 ear at least 4 hr before effect is required; reapply every 3 days as needed
1 mg over 3 days transdermal patch
- Apply 1 patch by transdermal route to the hairless area behind 1 ear at least 4 hr before effect is required; reapply every 3 days as needed
scopolamine 1 mg over 3 days transdermal patch
- Apply 1 patch by transdermal route to the hairless area behind 1 ear at least 4 hr before effect is required; reapply every 3 days as needed
Motion sickness
- Apply 1 patch by transdermal route to the hairless area behind 1 ear at least 4 hr before effect is required; reapply every 3 days as needed
Prevention of motion sickness
- Apply 1 patch by transdermal route to the hairless area behind 1 ear at least 4 hr before effect is required; reapply every 3 days as needed
- pramlintide
- Symlinpen 120
- Symlinpen 60
Contraindicated
- K-tab
- Klor-con
- Klor-con 10
- Klor-con M10
- Klor-con M15
- Klor-con M20
- Medi-lyte
- potassium chloride
- potassium citrate
- potassium Cl-calcium phos-mag
- sodium Cl-potassium chloride
- Thermotabs
- Urocit-k 10
- Urocit-k 15
- Urocit-k 5
Severe
Moderate
- Adasuve
- chlorpromazine
- Compazine
- Compro
- fluphenazine decanoate
- fluphenazine HCl
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- loxapine
- loxapine succinate
- Loxitane
- perphenazine
- perphenazine-amitriptyline
- Phenadoz
- Phenergan
- prochlorperazine
- prochlorperazine Edisylate
- prochlorperazine maleate
- promethazine
- Promethazine Vc
- Promethazine Vc-codeine
- promethazine-codeine
- promethazine-DM
- promethazine-phenyleph-codeine
- promethazine-phenylephrine
- Promethegan
- thioridazine
- trifluoperazine
- Angle-closure glaucoma
- Magnetic resonance imaging
- Severe pre-eclampsia
Contraindicated
- Open angle glaucoma
- Systemic mastocytosis
Severe
Moderate
- Bladder outflow obstruction
- Kidney disease with reduction in GFR
- Psychotic disorder
- Pyloroduodenal obstruction
- Seizure disorder
- Severe hepatic disease
TRANSDERM-SCOP (SCOPOLAMINE HYDROBROMIDE)
- Prevention of motion sickness
- Motion sickness
- Prevention of post-operative nausea and vomiting
- None
- Constipation
- Decreased sweating
- Dizziness
- Drowsy
- Memory impairment
More Frequent
Severe
Less Severe
- Visual changes
- Acute confusion
- Agitation
- Blurred vision
- Breast milk flow decreased
- Mydriasis
- Pharyngitis
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Drug-induced psychosis
- Hallucinations
- Ocular hypertension
- Orthostatic hypotension
- Paranoid disorder
- Secondary angle-closure glaucoma
- Seizure disorder
- Skin rash
- Urticaria
Less Severe
- Acute pain at drug application site
- Amblyopia
- Ataxia
- Disturbance of attention
- Dry eye
- Dysuria
- Erythema
- False sense of well-being
- Flatulence
- General weakness
- Headache disorder
- Insomnia
- Nausea
- Nervousness
- Ocular itching
- Skin irritation
- Vertigo
- Vomiting
Contraindicated
None
Severe Precaution
Scopolamine (Transderm)
No safety and efficacy established. Increased sensitivity to adverse effects including mydriasis, hallucinations, amblyopia and drug withdrawal syndrome.
- 1 Day – 18 Years
- No safety and efficacy established. Increased sensitivity to adverse effects including mydriasis, hallucinations, amblyopia and drug withdrawal syndrome.
Management or Monitoring Precaution
None
Scopolamine
- Severity Level:
2
- Additional Notes: Limited data suggest seizures in pre-eclamptic women exposed to scopolamine.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Scopolamine
Insufficient data available; long term use may decrease milk production
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Insufficient data available; long term use may decrease milk production |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Scopolamine
Neuro/Psych-Anticholinergic effects may cause sedation, hallucinations, dizziness, worsen cognitive impairment and increase fall risk. Non-sedating agents preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Motion sickness | |
| T75.3xxA | Motion sickness, initial encounter |
| 0-9 | A-Z |
|---|---|
| T75.3xxA | Motion sickness, initial encounter |
Formulary Reference Tool